Cite
MLA Citation
Jens Köhler and Martin Schuler. “LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.” Future oncology, vol. 10, 2014, pp. 533–540. http://access.bl.uk/ark:/81055/vdc_100140408434.0x000003